UMIT Private University for Health Sciences Medical Informatics and Technology: Results of a Collaborative Study at Campus Tyrol Argue in Favor of a Personalized Prostate Cancer Screening Approach

Food and Healthcare Press Releases Tuesday July 4, 2017 09:00
HALL, Austria--4 Jul--PRNewswire/InfoQuest

A simulation study published in BMC Public Health by researchers of the Tyrolean Health and Life Sciences University UMIT, the Oncotyrol center, the Medical University of Innsbruck and the University of Toronto highlights optimized use of prostate cancer screening.

(Photo: http://mma.prnewswire.com/media/529873/UMIT_Dr_Uwe_Siebert.jpg )
(Photo: http://mma.prnewswire.com/media/529874/UMIT_Nikolai_Muhlberger.jpg )

"Like most medical procedures also screening harbors benefits and risks. This gains increasing attention by the public," explains Prof. Dr. Uwe Siebert, Chair of the Department of Public Health, Health Services Research and Health Technology Assessment at UMIT and President-Elect of the Society for Medical Decision Making. "A major risk of prostate cancer screening is that of overdiagnosis and overtreatment. This refers to the diagnosis and treatment of clinically irrelevant tumors, which would not cause any complaints during men's lifetime and remain undetected without screening. Currently, there is no reliable method to distinguish clinically relevant from clinically irrelevant tumors. In consequence, also clinically irrelevant tumors may be treated, which unnecessarily exposes the affected patients to the unfortunately not uncommon long-term treatment complications such as erectile dysfunction, incontinence, bowel dysfunction."

The simulation model developed by the researchers within a ONCOTYROL research project for personalized medicine simulates the positive and negative effects of screening on the duration and quality of life of screening participants and analyses under which circumstances the potential harms of screening outweigh the potential benefits. Project Coordinator Ass. Prof. Dr. Nikolai Muhlberger summarizes the study findings as follows: "The study results suggest that participation in screening reduces the risk to die from prostate cancer and prolongs the life expectancy of participating men. However, when quality-of-life effects are considered as well, it is shown that primarily men with elevated familial prostate cancer risk benefit from screening, while in men with average prostate cancer risk overall the harms of screening prevail. In addition, the simulation predicts that the benefit of screening in men with elevated familial risk also strongly depends on their individual valuation of treatment-related long-term side-effects."

The urological experts in the research team, Prof. Dr. Wolfgang Horninger und Prof. Dr. Helmut Klocker, see the study as an important contribution towards a targeted application of prostate cancer screening. Horninger, the Dean of the Department of Urology at the Medical University of Innsbruck explains: "The study highlights the problem of overdiagnosis and illustrates the dependency of screening benefits on individual risk factors and preferences. Thus, it contributes to the improvement of patient counseling and supports an individual use of screening examinations, which all of us consider as important issues."

Contact: Prof. Dr. Uwe Siebert,   public-health@umit.at , +4350-8648-673930
Source: UMIT - The Health & Life Sciences University

Latest Press Release

U.S. FDA Determines Celliant(R) Responsive Textile Products Meet Criteria as Medical Devices and General Wellness Products

- Celliant-engineered products clinically proven to promote increased localized blood flow - FDA determination to usher in new era of performance fabrics, responsive textiles Hologenix, LLC, maker of Celliant , the world's most advanced, clinically...

PerkinElmer Launches VICTOR(R) Nivo(TM) Multimode Plate Reader

Multiple Detection Modes and Intuitive Software Help to Simplify and Accelerate Disease Research and Drug Discovery PerkinElmer, Inc. , a global leader committed to innovating for a healthier world, announced on July 24 (US-time) the launch of its new...

EMA#s CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma

- If approved, avelumab could be the first immunotherapy treatment indicated for this rare and aggressive skin cancer in the EU - Decision by the EC is expected in the third quarter of 2017 Merck and Pfizer Inc. (NYSE: PFE) today announced that the...

Do you know new repellent technology INSECT SHIELD was now launched in Thailand

INSECT SHIELD was developed in USA since 1996 at a request by US Military to terminate Lyme Disease brought by Ticks. As a result of 7 years testing and experiments, now US Army and Marine adopts INSECT SHIELD technology to their uniforms. INSECT SHIELD...

Cenegermin Eye Drops Receive European Union Approval: The First Biotechnological Drug Resulting from Dompe Research for the Treatment of Moderate to Severe Neurotrophic Keratitis is Made in Italy

- Behind the development of cenegermin are decades of Italian research, stemming from the studies of Rita Levi Montalcini, winner of the Nobel Prize in Medicine for the discovery of the nerve growth factor (NGF). - In 2015, the product was designated as...

Related Topics